skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PharmaLogo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

46 Total results for product and free and sample content found

Trialtrove

Revised and Newly Added Oncology Refractory/Relapsed Patient Segments in Trialtrove

By Citeline Oncology Editorial Team 15 Jun 2018

In oncology trials, patients are often differentiated based on line of therapy (LOT) for their current disease stage.  Briefly, patients can be naïve/untreated (First line), treated before or after surgery/radiation (Neoadjuvant and Adjuvant), treated after progressing on a previous line of therapy (Second line or greater) or treated to maintain a positive response (Maintenance/Consolidation).  In Trialtrove, these LOT patient segments have been applied to most oncological disease trials for almost a decade.

Topic Cancer

Read blog

Trialtrove

Type 2 Diabetes and Heart Failure - New Spotlight on an Old Problem

By Jake Mathon 08 Jun 2018

It has long been known that diabetes is a risk factor for heart failure. Analysis from the Framingham Heart Study established that men with type 2 diabetes had a 2.4-fold increase in heart failure and women had a five-fold increase. This link between the diseases is not just one way as more recent research has found the reverse to be in effect as well, that heart failure indeed is its own risk factor for diabetes mellitus.

Topic Diabetes

Read blog

Datamonitor Healthcare

Autologous Stem Cell Therapy for Multiple Sclerosis DeMISTified

24 May 2018

Phase III MIST trial data presented at the 2018 annual meeting of the American Academy of Neurology (AAN) highlight autologous hematopoietic stem cell therapy (aHSCT) as a radically novel prospect for multiple sclerosis (MS) treatment, with an unprecedented curative potential. Certainly, aHSCT’s potential to reverse disability is markedly distinct from currently available disease-modifying therapies (DMTs), which can only slow disability progression.

Read blog

Trialtrove

Clinical Research on the Wearable Technology Bandwagon

By Laurie Withington 09 May 2018

The wearable technology market is rapidly growing, and impacting many different areas of our culture such as social interaction, entertainment, environment, self-awareness, and healthcare. Techcrunch has forecasted sales of wearable devices worldwide this year at $30.5BN in total revenue . As more money is spent on wearable devices, innovation expands, which in turn increases the many facets of our lives that these devices can be incorporated into.

Topic Clinical trials

Read blog

Pharmaprojects

Drug Development for Eating Disorders and Obesity – Weighing Up the Difference. Part II

By Pippa Nutkins 18 Apr 2018

After our review of the drug development landscape for eating disorders, we investigated the latest research trends and pharmacological interventions for the escalating global obesity epidemic. The argument that eating disorders and obesity are similarly manifested in genetic, metabolic and psychological origins could be an important consideration for drug development in these two complex indications. Are such similarities reflected in the drug development pipelines and what are the prospects for these multifactorial diseases?

Topic Drug development landscape

Read blog

Pharmaprojects

Drug Development for Eating Disorders and Obesity - Weighing Up the Difference Part II

By Pippa Nutkins 02 Mar 2018

We investigated the latest research trends and pharmacological interventions for the escalating global obesity epidemic. The argument that eating disorders and obesity are similarly manifested in genetic, metabolic and psychological origins could be an important consideration for drug development in these two complex indications.

Topic Drug development landscape

Read blog

Pharmaprojects, Trialtrove

Spotlight on Huntington's Disease for #Rare Disease Day

By Judy Adair 28 Feb 2018

February 28, 2018 is the eleventh international #Rare Disease Day.  This day is designed to raise awareness about rare diseases and their impact on patient’s lives to public and decision-makers in government and health fields.  Scrutiny of rare diseases is vital as there are approximately 7,000 different types of rare diseases and approximately 80 percent are caused by faulty genes [1].  This paper will focus on one, Huntington’s Disease (HD).

Topic Rare Disease

Read blog

Pharmaprojects

Drug Development for Eating Disorders and Obesity - Weighing Up the Difference. Part I

By Angela Kwan 27 Feb 2018

As Eating Disorder Awareness Week gets under way for 2018, we reviewed the latest pharmacological interventions for three of the most common eating disorders (anorexia nervosa, bulimia nervosa and binge eating disorder) and obesity in a two part blog series, to uncover the emerging trends in these fields and consider what it might mean for future therapeutic development.

Topic Drug development landscape

Read blog

Trialtrove, Pharmaprojects

2018 - the year of successful migraine prophylaxis therapies

By Daniel Digaudio 13 Feb 2018

It is essential that a truly effective prophylactic migraine medicine is found. Many currently available migraine therapies are acute and provide the patient with some relief after the onset of a migraine, whereas preventative medicines are extremely limited and not entirely effective. This blog will look at the past, present, and future of migraine prophylaxis.

Topic Drug development landscape

Read blog
Show More

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now